{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:28:54Z","timestamp":1773350934760,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/ajp.0b013e318175920f","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T07:13:38Z","timestamp":1221549218000},"page":"685-689","source":"Crossref","is-referenced-by-count":23,"title":["An Open-label Pilot Trial of Ibandronate for Complex Regional Pain Syndrome"],"prefix":"10.1097","volume":"24","author":[{"given":"Brenda","family":"Breuer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukiat","family":"Ongseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-I","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210204","first-page":"79","article-title":"Reflex Sympathetic Dystrophy: A Reappraisal","author":"Boas","year":"1997"},{"issue":"suppl","key":"R2-6-20210204","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/00002508-200006001-00004","article-title":"Peripheral neuropathic pain: from mechanisms to symptoms","volume":"16","author":"Baron","year":"2000","journal-title":"Clin J Pain"},{"key":"R3-6-20210204","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pain.2006.09.008","article-title":"The incidence of complex regional pain syndrome: a population-based study","volume":"129","author":"de Mos","year":"2007","journal-title":"Pain"},{"key":"R4-6-20210204","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0304-3959(03)00065-4","article-title":"Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study","volume":"103","author":"Sandroni","year":"2003","journal-title":"Pain"},{"key":"R5-6-20210204","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pain.2003.08.009","article-title":"Prospective examination of pain-related and psychological predictors of CRPS-like phenomena following total knee arthroplasty: a preliminary study","volume":"106","author":"Harden","year":"2003","journal-title":"Pain"},{"key":"R6-6-20210204","article-title":"The Neurological Basis of Pain","author":"Baron","year":"2005"},{"key":"R7-6-20210204","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02238763","article-title":"Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate","volume":"16","author":"Cortet","year":"1997","journal-title":"Clin Rheumatol"},{"key":"R9-6-20210204","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard.56.3.201","article-title":"Bisphosphonate therapy of reflex sympathetic dystrophy syndrome","volume":"56","author":"Adami","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"R10-6-20210204","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/ard.54.8.687-a","article-title":"Treatment of refractory reflex sympathetic dystrophy with pamidronate","volume":"54","author":"Maillefert","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"R11-6-20210204","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/rheumatology\/40.12.1394","article-title":"Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases","volume":"40","author":"Kubalek","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"R12-6-20210204","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.bor.0000231913.32364.32","article-title":"Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease [Review]","volume":"18","author":"Boyce","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R13-6-20210204","first-page":"13","article-title":"Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate","volume":"19","author":"Van Offel","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"R14-6-20210204","first-page":"1477","article-title":"Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study","volume":"27","author":"Varenna","year":"2000","journal-title":"J Rheumatol"},{"key":"R15-6-20210204","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0885-3924(03)00201-X","article-title":"Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records","volume":"26","author":"Pappagallo","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"R16-6-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0304-3959(00)00447-4","article-title":"Analgesic effect of bisphosphonates in mice","volume":"91","author":"Bonabello","year":"2001","journal-title":"Pain"},{"key":"R17-6-20210204","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"key":"R18-6-20210204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/mol.56.1.131","article-title":"Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs","volume":"56","author":"Benford","year":"1999","journal-title":"Mol Pharmacol"},{"key":"R19-6-20210204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3959(99)00011-1","article-title":"External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain","volume":"81","author":"Bruehl","year":"1999","journal-title":"Pain"},{"key":"R20-6-20210204","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R21-6-20210204","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"R22-6-20210204","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"R23-6-20210204","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.mlg.0000187398.51857.3c","article-title":"Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates","volume":"116","author":"Farrugia","year":"2006","journal-title":"Laryngoscope"},{"key":"R24-6-20210204","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.tripleo.2004.08.001","article-title":"Intravenous bisphosphonates and osteonecrosis","volume":"98","author":"Greenberg","year":"2004","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"R25-6-20210204","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"key":"R26-6-20210204","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"R27-6-20210204","first-page":"111","article-title":"Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy","volume":"71","author":"Melo","year":"2005","journal-title":"J Can Dent Assoc"},{"key":"R28-6-20210204","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.joms.2003.11.003","article-title":"Bisphosphonates and bone necrosis","volume":"62","author":"Pogrel","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl","key":"R29-6-20210204","doi-asserted-by":"crossref","first-page":"48","DOI":"10.47102\/annals-acadmedsg.V33N4p48S","article-title":"Bisphosphonates: a word of caution","volume":"33","author":"Robinson","year":"2004","journal-title":"Ann Acad Med Singapore"},{"key":"R30-6-20210204","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"R31-6-20210204","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Woo","year":"2005","journal-title":"N Engl J Med"},{"key":"R32-6-20210204","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"R33-6-20210204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000055294","article-title":"Greek brief pain inventory: validation and utility in cancer pain","volume":"60","author":"Mystakidou","year":"2001","journal-title":"Oncology"},{"key":"R34-6-20210204","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1212\/WNL.48.2.332","article-title":"Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale","volume":"48","author":"Galer","year":"1997","journal-title":"Neurology"},{"key":"R35-6-20210204","article-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"R36-6-20210204","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood \u03b3\u03b4 T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R37-6-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00063030-200418040-00004","article-title":"Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities [Review]","volume":"18","author":"Santini","year":"2004","journal-title":"Biodrugs"},{"key":"R38-6-20210204","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","article-title":"Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6","volume":"23","author":"Dicuonzo","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"R39-6-20210204","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/JCD:5:2:143","article-title":"Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass","volume":"5","author":"Younes","year":"2002","journal-title":"J Clin Densitometry"},{"issue":"suppl 6","key":"R40-6-20210204","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(01)90262-3","article-title":"Zoledronic acid in cancer patients with bone metastases: results of phase I and II trials [Review]","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin Oncol"},{"key":"R41-6-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"R42-6-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pain.2004.10.019","article-title":"Consensus on outcome measures for chronic pain trials","volume":"113","author":"McQuay","year":"2005","journal-title":"Pain"}],"container-title":["The Clinical Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AJP.0b013e318175920f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T20:07:44Z","timestamp":1709237264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002508-200810000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ajp.0b013e318175920f","relation":{},"ISSN":["0749-8047"],"issn-type":[{"value":"0749-8047","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}